{"id":9722,"date":"2026-03-11T11:14:52","date_gmt":"2026-03-11T16:14:52","guid":{"rendered":"https:\/\/fifarma.org\/?post_type=publicaciones&#038;p=9722"},"modified":"2026-03-11T11:21:02","modified_gmt":"2026-03-11T16:21:02","slug":"fifarma-time-to-vax-2025","status":"publish","type":"publicaciones","link":"https:\/\/fifarma.org\/en\/publicaciones\/fifarma-time-to-vax-2025\/","title":{"rendered":"FIFARMA Time to Vax 2025"},"content":{"rendered":"<p class=\"wp-block-paragraph\">O <strong>FIFARMA Time to Vax 2025<\/strong>, desenvolvido pela FIFARMA em colabora\u00e7\u00e3o com a IQVIA, \u00e9 o primeiro estudo regional que analisa o acesso e a disponibilidade de vacinas inovadoras em doze pa\u00edses da Am\u00e9rica Latina. Com base em uma metodologia inspirada no indicador da European Federation of Pharmaceutical Industries and Associations (EFPIA), o relat\u00f3rio avalia 29 vacinas aprovadas globalmente entre 2010 e 2025, examinando o tempo at\u00e9 sua aprova\u00e7\u00e3o local, os n\u00edveis de disponibilidade p\u00fablica e privada e o papel do Fundo Rotat\u00f3rio da Organiza\u00e7\u00e3o Pan-Americana da Sa\u00fade. O estudo identifica avan\u00e7os, mas tamb\u00e9m lacunas persistentes entre a aprova\u00e7\u00e3o e a cobertura p\u00fablica, contribuindo com evid\u00eancias para fortalecer o acesso oportuno a vacinas inovadoras na regi\u00e3o.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><a href=\"https:\/\/fifarma.org\/wp-content\/uploads\/2026\/03\/IQVIA-FIFARMA_Time-to-Vax-2025_Report.pdf\" type=\"link\" id=\"https:\/\/fifarma.org\/wp-content\/uploads\/2026\/03\/IQVIA-FIFARMA_Time-to-Vax-2025_Report.pdf\">Ver documento<\/a><\/strong><\/p>\n\n    <div class=\"xs_social_share_widget xs_share_url after_content \t\tmain_content  wslu-style-1 wslu-share-box-shaped wslu-fill-colored wslu-none wslu-share-horizontal wslu-theme-font-no wslu-main_content\">\n\n\t\t\n        <ul>\n\t\t\t        <\/ul>\n    <\/div>","protected":false},"author":26,"parent":0,"template":"","ano":[184],"idioma":[56],"etiquetas-publicacion":[57],"categoria-publicacion":[],"class_list":["post-9722","publicaciones","type-publicaciones","status-publish","hentry","ano-184","idioma-portugues","etiquetas-publicacion-ecosistemas-de-innovacion"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.7 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FIFARMA Time to Vax 2025 - FIFARMA<\/title>\n<meta name=\"description\" content=\"O estudo Time to Vax 2025 da FIFARMA, desenvolvido com a IQVIA, analisa o acesso a vacinas inovadoras na Am\u00e9rica Latina e as lacunas entre aprova\u00e7\u00e3o e disponibilidade em 12 pa\u00edses.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fifarma.org\/en\/publications\/fifarma-time-to-vax-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FIFARMA Time to Vax 2025\" \/>\n<meta property=\"og:description\" content=\"O estudo Time to Vax 2025 da FIFARMA, desenvolvido com a IQVIA, analisa o acesso a vacinas inovadoras na Am\u00e9rica Latina e as lacunas entre aprova\u00e7\u00e3o e disponibilidade em 12 pa\u00edses.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fifarma.org\/en\/publications\/fifarma-time-to-vax-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"FIFARMA\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-11T16:21:02+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-time-to-vax-2025\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-time-to-vax-2025\\\/\",\"name\":\"FIFARMA Time to Vax 2025 - FIFARMA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\"},\"datePublished\":\"2026-03-11T16:14:52+00:00\",\"dateModified\":\"2026-03-11T16:21:02+00:00\",\"description\":\"O estudo Time to Vax 2025 da FIFARMA, desenvolvido com a IQVIA, analisa o acesso a vacinas inovadoras na Am\u00e9rica Latina e as lacunas entre aprova\u00e7\u00e3o e disponibilidade em 12 pa\u00edses.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-time-to-vax-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-time-to-vax-2025\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-time-to-vax-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/fifarma.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publicaciones\",\"item\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FIFARMA Time to Vax 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"name\":\"FIFARMA\",\"description\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"publisher\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fifarma.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\",\"name\":\"Fifarma\",\"alternateName\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"contentUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"width\":195,\"height\":39,\"caption\":\"Fifarma\"},\"image\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FIFARMA Time to Vax 2025 - FIFARMA","description":"O estudo Time to Vax 2025 da FIFARMA, desenvolvido com a IQVIA, analisa o acesso a vacinas inovadoras na Am\u00e9rica Latina e as lacunas entre aprova\u00e7\u00e3o e disponibilidade em 12 pa\u00edses.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fifarma.org\/en\/publications\/fifarma-time-to-vax-2025\/","og_locale":"en_US","og_type":"article","og_title":"FIFARMA Time to Vax 2025","og_description":"O estudo Time to Vax 2025 da FIFARMA, desenvolvido com a IQVIA, analisa o acesso a vacinas inovadoras na Am\u00e9rica Latina e as lacunas entre aprova\u00e7\u00e3o e disponibilidade em 12 pa\u00edses.","og_url":"https:\/\/fifarma.org\/en\/publications\/fifarma-time-to-vax-2025\/","og_site_name":"FIFARMA","article_modified_time":"2026-03-11T16:21:02+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fifarma.org\/publicaciones\/fifarma-time-to-vax-2025\/","url":"https:\/\/fifarma.org\/publicaciones\/fifarma-time-to-vax-2025\/","name":"FIFARMA Time to Vax 2025 - FIFARMA","isPartOf":{"@id":"https:\/\/fifarma.org\/#website"},"datePublished":"2026-03-11T16:14:52+00:00","dateModified":"2026-03-11T16:21:02+00:00","description":"O estudo Time to Vax 2025 da FIFARMA, desenvolvido com a IQVIA, analisa o acesso a vacinas inovadoras na Am\u00e9rica Latina e as lacunas entre aprova\u00e7\u00e3o e disponibilidade em 12 pa\u00edses.","breadcrumb":{"@id":"https:\/\/fifarma.org\/publicaciones\/fifarma-time-to-vax-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fifarma.org\/publicaciones\/fifarma-time-to-vax-2025\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fifarma.org\/publicaciones\/fifarma-time-to-vax-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fifarma.org\/"},{"@type":"ListItem","position":2,"name":"Publicaciones","item":"https:\/\/fifarma.org\/publicaciones\/"},{"@type":"ListItem","position":3,"name":"FIFARMA Time to Vax 2025"}]},{"@type":"WebSite","@id":"https:\/\/fifarma.org\/#website","url":"https:\/\/fifarma.org\/","name":"FIFARMA","description":"Latin American Federation of the Pharmaceutical Industry","publisher":{"@id":"https:\/\/fifarma.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fifarma.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fifarma.org\/#organization","name":"Fifarma","alternateName":"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica","url":"https:\/\/fifarma.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/","url":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","contentUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","width":195,"height":39,"caption":"Fifarma"},"image":{"@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/publicaciones\/9722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/publicaciones"}],"about":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/types\/publicaciones"}],"author":[{"embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/users\/26"}],"wp:attachment":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/media?parent=9722"}],"wp:term":[{"taxonomy":"ano","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/ano?post=9722"},{"taxonomy":"idioma","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/idioma?post=9722"},{"taxonomy":"etiquetas-publicacion","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/etiquetas-publicacion?post=9722"},{"taxonomy":"categoria-publicacion","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/categoria-publicacion?post=9722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}